Affordable Access

Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.

Authors
  • Bruzzone, M
  • Catsafados, E
  • Miglietta, L
  • Amoroso, D
  • Pedulla, F
  • Giannessi, P G
  • Locatelli, M C
  • D'Antona, A
  • Foglia, G
  • Mammoliti, S
  • Turno, F
  • Gentile, A
  • Nicosia, F
  • Luporini, G
  • Ragni, N
  • Boccardo, F
Type
Published Article
Journal
Oncology
Publication Date
Jan 01, 1996
Volume
53
Issue
5
Pages
349–353
Identifiers
PMID: 8784466
Source
Medline
License
Unknown

Abstract

Encouraging results with Paclitaxel are reported in ovarian cancer patients relapsing and progressing after platinum-based chemotherapy; however, the two populations have different probabilities of a response to a second-line treatment. Here we report the results achieved in 39 patients with platinum-refractory ovarian cancer, treated with Paclitaxel 175 mg/qm2 (or 135 mg/m2 if heavily pretreated) using 3-hour intravenous infusion every 3 weeks, in an attempt to verify the activity of this drug in platinum-resistant patients. The toxicity was mild to moderate and primarily hematologic and neurologic. The objective response rate is 12.8% with no complete responses. The response duration was brief and the median survival 6 (range 1-17) months. An accurate cost-benefit balance is necessary before routinely use of Paclitaxel in platinum-refractory patients. Further research is needed to determine the optimal role of Paclitaxel in the whole therapeutic strategy for ovarian cancer.

Report this publication

Statistics

Seen <100 times